Checkpoint Therapeutics, Inc. (CKPT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Checkpoint Therapeutics, Inc. (CKPT) Healthcare & Pipeline Overview

Checkpoint Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in the acquisition, development, and potential commercialization of innovative cancer treatments, particularly immunotherapies and targeted oncology solutions, positioning them within the competitive landscape of companies addressing solid tumor malignancies.

What Is the Investment Thesis for CKPT?

Checkpoint Therapeutics presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of Cosibelimab, their lead PD-L1 antibody, and Olafertinib, their EGFR inhibitor. Positive clinical trial results and regulatory approvals are key catalysts. The company's market capitalization of $368M reflects the speculative nature of its pipeline. A successful Phase 3 trial for Cosibelimab could significantly increase the company's valuation. Ongoing: Collaboration agreements, such as the one with TG Therapeutics, provide potential revenue streams and validation of their technology. Potential: Risks include clinical trial failures, regulatory hurdles, and the need for additional capital, which could dilute existing shareholders.

Based on FMP financials and quantitative analysis

CKPT Key Highlights

• Checkpoint Therapeutics is a clinical-stage company with a focus on immunotherapy and targeted oncology.
• The lead product candidate, Cosibelimab, is a fully-human monoclonal antibody targeting PD-L1.
• Developing Olafertinib, a third-generation EGFR inhibitor for non-small cell lung cancer.
• Market capitalization of $368M reflects the speculative nature of its pipeline.
• Collaboration agreements with companies like TG Therapeutics provide potential revenue streams.

Who Are CKPT's Competitors?

CKPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CKPT's Key Strengths?

• Novel immunotherapy and targeted oncology pipeline.
• Lead product candidate, Cosibelimab, has shown promising clinical data.
• Experienced management team with expertise in drug development.
• Collaboration agreements with other companies in the pharmaceutical industry.

What Are CKPT's Weaknesses?

• Clinical-stage company with no currently marketed products.
• Reliance on the successful development and commercialization of its product candidates.
• High R&D spending and long development timelines.
• Dependence on Fortress Biotech, Inc.

What Could Drive CKPT Stock Higher?

• Data readout from ongoing Phase 3 trials of Cosibelimab.
• Regulatory submissions for Cosibelimab in various solid tumor indications.
• Advancement of Olafertinib through clinical trials.
• Potential partnerships with larger pharmaceutical companies.

What Are the Key Risks for CKPT?

• Financial-distress signal — its Altman Z-Score of -9.25 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Cosibelimab or other product candidates.
• Regulatory delays or rejection of regulatory submissions.
• Competition from other companies developing cancer therapies.
• Need for additional capital to fund ongoing operations.

What Are the Growth Opportunities for CKPT?

• Growth opportunity 1: Successful clinical trials and regulatory approval of Cosibelimab for various solid tumor indications represent a significant growth opportunity. The market for PD-L1 inhibitors is substantial, with existing drugs generating billions in annual revenue. If Cosibelimab demonstrates superior efficacy or safety compared to existing therapies, it could capture a significant share of this market. Timeline: Ongoing Phase 3 trials with potential FDA submission in the next 12-18 months.
• Growth opportunity 2: The development and commercialization of Olafertinib, a third-generation EGFR inhibitor, offers another growth avenue. The market for EGFR inhibitors in non-small cell lung cancer is well-established, but there is still a need for more effective and less toxic therapies. Positive clinical trial results could lead to regulatory approval and commercial success. Timeline: Ongoing clinical trials with potential data readout in the next 24 months.
• Growth opportunity 3: Expanding the pipeline through strategic acquisitions or in-licensing of promising oncology assets could drive future growth. The company's expertise in immunotherapy and targeted oncology makes it well-positioned to identify and develop novel therapies. Timeline: Ongoing efforts to evaluate potential assets for acquisition or in-licensing.
• Growth opportunity 4: Securing partnerships with larger pharmaceutical companies for the development and commercialization of its pipeline products could provide significant financial and strategic benefits. Partnerships can provide access to resources, expertise, and global markets. Timeline: Ongoing discussions with potential partners.
• Growth opportunity 5: Expanding into new geographic markets, particularly in Asia and Europe, could drive revenue growth. The incidence of cancer is increasing globally, creating a growing demand for innovative therapies. Timeline: Potential expansion into new markets following regulatory approval in the United States.

What Opportunities Does CKPT Have?

• Successful clinical trials and regulatory approval of its product candidates.
• Expansion of its pipeline through strategic acquisitions or in-licensing.
• Partnerships with larger pharmaceutical companies for commercialization.
• Expansion into new geographic markets.

What Threats Does CKPT Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other companies developing cancer therapies.
• Need for additional capital.

What Are CKPT's Competitive Advantages?

• Proprietary technology and intellectual property related to its product candidates.
• Clinical data supporting the safety and efficacy of its product candidates.
• Strategic partnerships with other companies in the pharmaceutical industry.

What Does CKPT Do?

Checkpoint Therapeutics, Inc., founded in 2014 and based in Waltham, Massachusetts, is a clinical-stage immunotherapy and targeted oncology company dedicated to acquiring, developing, and commercializing novel treatments for patients suffering from solid tumor cancers. As a subsidiary of Fortress Biotech, Inc., Checkpoint Therapeutics focuses on innovative approaches to combat cancer through targeted therapies and immunotherapies. The company's lead product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype. Cosibelimab directly binds to programmed death ligand-1 (PD-L1), effectively blocking its interaction with programmed death receptor-1 and B7.1 receptors. This mechanism is crucial for enhancing the body's immune response against cancer cells. In addition to Cosibelimab, Checkpoint Therapeutics is developing CK-302, a human agonistic antibody designed to bind to and trigger signaling in GITR expressing cells, further stimulating the immune system. The company's pipeline also includes Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, which is being developed as a treatment for patients with EGFR mutation-positive non-small cell lung cancer. Furthermore, Checkpoint Therapeutics is advancing CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains, and an anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody designed to recognize CAIX expressing cells and induce cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics also has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets related to licenses in the field of hematological malignancies.

What Products and Services Does CKPT Offer?

• Develops and commercializes novel treatments for solid tumor cancers.
• Focuses on immunotherapy and targeted oncology approaches.
• Lead product candidate is Cosibelimab, a PD-L1 inhibitor.
• Developing CK-302, a human agonistic antibody targeting GITR.
• Developing Olafertinib, a third-generation EGFR inhibitor for non-small cell lung cancer.
• Developing CK-103, a small molecule inhibitor of bromodomain and extra-terminal bromodomains.
• Developing anti-carbonic anhydrase IX (CAIX) antibody.

How Does CKPT Make Money?

• Acquires and develops novel oncology assets.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Seeks regulatory approval from the FDA and other regulatory agencies.
• Commercializes its products directly or through partnerships.

What Industry Does CKPT Operate In?

Checkpoint Therapeutics operates within the biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory oversight. The market for cancer therapeutics is substantial and growing, driven by an aging population and advances in personalized medicine. Competition is intense, with numerous companies developing novel therapies. Checkpoint Therapeutics differentiates itself through its focus on fully-human antibodies and targeted small molecule inhibitors. The company's success depends on its ability to navigate the complex regulatory landscape and secure partnerships for commercialization.

Who Are CKPT's Key Customers?

• Patients with solid tumor cancers.
• Oncologists and other healthcare professionals.
• Hospitals and cancer centers.

How Checkpoint Therapeutics, Inc. Is Valued

Checkpoint Therapeutics, Inc. carries a market capitalization of $368M, placing it in the small-cap category. Relative to its peer group, CKPT's quantitative score of 43/100 is below the peer average of 72/100.

Key Financial Metrics

Its free cash flow yield is -5.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.91 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9Financial Health

Checkpoint Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.25 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Checkpoint Therapeutics, Inc. revenue of about $185.7M for fiscal 2026, with EPS near $1.13.

CKPT Financials

CKPT Latest News

CKPT Analyst Consensus

CKPT MoonshotScore

CKPT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources